Sonic Healthcare (STU:SAB) Growth Rank: 4 (As of Sep. 06, 2026) — 56% Below Median

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:SAB Sonic Healthcare Ltd STU:SAB
72 GF Score
Price €11.90
GF Value €18.88
Valuation Significantly Undervalued
! 5 Warning Signs
View Full Analysis

What is Sonic Healthcare Growth Rank?

Sonic Healthcare STU:SAB -1.23% 72 Growth Rank is 4 as of Sep. 06, 2026, which is 56% below its 10-year median of 9.00. GuruFocus rates STU:SAB with a GF Score™ of 72/100 and a GF Value™ of €18.88 (Significantly Undervalued). The stock has 5 warning signs investors should review.

Sonic Healthcare has the Growth Rank of 4.

GuruFocus Growth Rank measures the growth of a company in terms of its revenue and profitability, rated on a scale from 1 to 10. Historically, the companies with the highest growth ranks performed the best over the long term. It is calculated using the following criteria:

1. 5-year revenue growth rate, the higher, the better.
2. 3-year revenue growth rate, the higher, the better.
3. 5-year EBITDA growth rate, the higher, the better.
4. The predictability of 5-year revenue. The most consistent it is, the higher the rank.

A higher score reflects a greater ability to drive business growth, with companies considered to have strong and sustainable expansion potential. Conversely, a lower score indicates challenges in achieving consistent growth and scalability.

GuruFocus found that the Growth Rank is the second of the two most-sensitive parameters among the five parameters checked. Please click GF Score to see more details on GF Score's 5 Key Aspects of Analysis.

Please note that we are using the five-year EBITDA growth rate as a parameter, so the company needs to have had positive growth over that time. The reason we use EBITDA instead of earnings per share is that with EBITDA, we can rank a lot more companies since a company may have positive EBITDA but negative EPS. Since we are looking at the growth here, EBITDA gives us a pretty clear picture about the growth in the company's business operations.

Sonic Healthcare Growth Rank Related Terms

STU:SAB vs TMO, DHR, NTRA: Growth Rank Comparison

For the Diagnostics & Research subindustry, Sonic Healthcare's Growth Rank, along with its competitors' market caps and Growth Rank data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Sonic Healthcare Growth Rank vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Sonic Healthcare's Growth Rank distribution charts can be found below:

* The bar in red indicates where Sonic Healthcare's Growth Rank falls into.


STU:SAB
72GF Score
Sonic Healthcare Ltd STU:SAB
Growth Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Growth Rank →
What does a Growth Rank of 4 mean?
Sonic Healthcare (STU:SAB) has a Growth Rank of 4 as of Sep. 06, 2026. Growth Rank measures the growth of a company in terms of its revenue and profitability. View historical data on Sonic Healthcare and its competitors. This is 56% below median its historical median of 9.00. Over the past decade, Sonic Healthcare's Growth Rank has ranged from 4.00 to 10.00.
Is Sonic Healthcare's Growth Rank too high?
Sonic Healthcare's current Growth Rank of 4 is 56% below median its 10-year median of 9.00. Over the past 10 years, this metric has ranged from a low of 4.00 to a high of 10.00. Overall, Sonic Healthcare has a GF Score™ of 72/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Sonic Healthcare's Growth Rank compare to TMO and DHR?
Sonic Healthcare's Growth Rank of 4 can be compared against companies in the Medical Diagnostics & Research industry. Historically, Sonic Healthcare's own Growth Rank has ranged from 4.00 to 10.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Growth Rank for a Medical Diagnostics & Research company?
A good Growth Rank depends on the Medical Diagnostics & Research industry context. However, Growth Rank should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Growth Rank mean?
A high Growth Rank can signal that a stock is expensive relative to its fundamentals. Growth Rank measures the growth of a company in terms of its revenue and profitability. View historical data on Sonic Healthcare and its competitors. Sonic Healthcare's current Growth Rank is 4, which is 56% below median its own 10-year median of 9.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sonic Healthcare stock overvalued right now?
Based on GuruFocus' analysis, Sonic Healthcare (STU:SAB) is currently considered Significantly Undervalued. The stock's GF Value™ is €18.88, compared to a current price of €11.90 — trading 36.9% below its estimated fair value. The current Growth Rank is 4, which is 56% below median its 10-year median of 9.00. Sonic Healthcare's overall GF Score™ is 72/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Growth Rank calculated?
Growth Rank is calculated from a company's financial statements. For Sonic Healthcare (STU:SAB), the current Growth Rank is 4 as of Sep. 06, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Sonic Healthcare (STU:SAB) Overvalued in 2026?

Based on GuruFocus' analysis, Sonic Healthcare stock appears to be undervalued. The current stock price of €11.90 is trading 36.9% below its estimated GF Value™ of €18.88. GuruFocus considers Sonic Healthcare to be Significantly Undervalued.

Key valuation signals for STU:SAB:

  • Growth Rank: 4 (56% below median its 10-year median of 9.00)
  • GF Value™: €18.88 vs. price of €11.90 (36.9% below fair value)
  • GF Score™: 72/100 with 5 warning signs

No single metric tells the full story. See the STU:SAB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Sonic Healthcare Business Description

Address 225 George Street, Level 22, Grosvenor Place, Sydney, NSW, AUS, 2000
Sonic Healthcare is a global pathology provider. It is the largest private operator in Australia, Germany, Switzerland and the UK, the second-largest in Belgium and New Zealand, and the third largest in the US. In addition to pathology, which contributes roughly 85% of group revenue, Sonic is the second-largest player in diagnostic imaging in Australia and the largest operator of medical centers in Australia. The company typically earns about 35% of group revenue in Australia and New Zealand, 25% in the US, and 40% in Europe.
72GF Score

Get the complete analysis for STU:SAB

Growth Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€11.90
Price
€18.88
GF Value